Development of Japanese Versions of the 4‐Item Mystical Experience Questionnaire and 7‐Item Challenging Experience Questionnaire
Futaba Umemura, Hiroko Kotajima‐Murakami, Justin C Strickland, Albert Garcia‐romeu, Matthew W. Johnson, Kazutaka Ikeda
Neuropsychopharmacology Reports August 27, 2026 DOI: 10.1002/npr2.70164 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Questionnaire translation and cultural adaptation study Peer reviewed |
|---|---|
| Measures | Mystical Experience Questionnaire (MEQ-4), Challenging Experience Questionnaire (CEQ-7) |
| Topics | Mystical experience |
| Key points | Developed authorized Japanese versions of the MEQ-4 and CEQ-7, enabling rapid assessment of mystical and challenging experiences in Japanese speakers; future validation is needed. |
Abstract
Introduction: Interest in therapeutic applications of psychedelics has recently resurged. Mystical-type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30-item Mystical Experience Questionnaire (MEQ-30) and the 26-item Challenging Experience Questionnaire (CEQ), respectively. The brief 4-item MEQ (MEQ-4) and 7-item CEQ (CEQ-7) may reduce respondent burden, but Japanese versions have not yet been developed. This study developed Japanese versions of the MEQ-4 and CEQ-7.
Methods: In translating the MEQ-4 and CEQ-7, our procedures were informed by the recommendations of the "Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation." Separately, experts in psychedelics reviewed semantic nuances and the naturalness and appropriateness of the Japanese wording. Cognitive debriefing was not conducted because recruiting an appropriate Japanese-speaking sample with psychedelic experience was not feasible.
Results: The final, approved back-translated versions of the MEQ-4 and CEQ-7 were developed, and the authorized Japanese versions of the MEQ-4 and CEQ-7 were established.
Conclusions: In the present study, Japanese versions of the MEQ-4 and CEQ-7 were developed, enabling more rapid and efficient assessments of mystical and challenging experiences among Japanese speakers. Future studies should evaluate their comprehensibility, interpretability, cultural appropriateness, reliability, and validity in Japanese-speaking samples.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Developed authorized Japanese versions of the MEQ-4 and CEQ-7 for assessing mystical and challenging experiences, with future validation still needed.
Synthesized
Comparable studies
Other cross-sectional and survey studies on mystical experience, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Of Roots and Fruits: A Comparison of Psychedelic and Nonpsychedelic Mystical Experiences Self-selected participants who reported a religious, spiritual, or mystical experience | 2016 | Cross-sectional survey | n = 739 |
| Illicit Use of LSD or Psilocybin, but not MDMA or Nonpsychedelic Drugs, is Associated with Mystical Experiences in a Dose-Dependent Manner Adults recruited from the MAPS website and newsletter, most reporting use of various... | 2012 | Cross-sectional survey | n = 337 |
| Peak Experiences: Some Empirical Tests Random sample of adults in the San Francisco Bay Area | 1978 | Cross-sectional survey | |
| Peak Experience Tendencies | 1982 | Cross-sectional survey | |
| Rhythmic Chanting and Mystical States across Traditions. Regular chanters across 33 countries | 2021 | Cross-sectional survey | n = 464 |
Citations in the library
Cites 19
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin Journal of Psychopharmacology October 6, 2015
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
- Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology Journal of Psychopharmacology November 16, 2016
and 14 more in the library